Navigation Links
Absolute Antibody Launches VivopureX™ Recombinant Antibodies for In Vivo Research
Date:1/7/2020

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced the launch of its VivopureX™ recombinant mouse antibodies for in vivo research in mouse models. The collection consists of popular antibody clones, many originally obtained from rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions to improve research results. The antibodies are all available in discounted bulk sizes ranging from 1 mg to 100 mg.

VivopureX™ antibodies are species-matched chimeric antibodies, consisting of a clone’s original antigen-binding variable domain with a mouse constant domain, which means they do not induce neutralizing antibodies in mouse models. As a result, the engineered recombinant antibodies offer many advantages compared to the original monoclonal antibodies, including increased long-term efficacy, stronger potency and a more consistent response across cohorts. In addition, VivopureX™ antibodies feature engineered effector functions, with Fc receptor binding tailored to best suit popular applications such as depletion, agonism or blocking.

All antibodies are produced recombinantly for ensured batch-to-batch reproducibility, and offer high purity and low endotoxin levels ideal for in vivo applications. The antibodies are targeted against key immune system proteins, including clinically relevant checkpoint proteins such as PD-1, CTLA-4 and OX40. Absolute Antibody data has shown that the recombinant mouse PD-1 antibody, based on the widely used clone RMP1-14, reduces tumor size in a mouse model more effectively than the original rat version.

“The VivopureX™ antibody collection includes a selection of our most exciting mouse-anti-mouse antibodies, now available at discounted bulk prices ideal for in vivo researchers,” said Dr. Michael Fiebig, Director of Products and Innovations at Absolute Antibody. “Most antibodies currently used in vivo are immunogenic, leading to adverse immunological reactions and gradual loss of activity. By applying the same protein engineering approaches used in therapeutic development to research reagents, we can improve in vivo research results and further our understanding into the mechanisms underlying immunotherapy.”

For more information, and a full list of available antibody targets, please visit our website here.

About Absolute Antibody, Ltd.
Absolute Antibody is a rapidly growing company with a vision to make recombinant antibody technology accessible to all. We offer antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies, engineered into new and useful formats. Visit absoluteantibody.com for more information.

Contact:
Lisa Merolla    
Director of Marketing
+1 617-377-4057 (extension 610)
l.merolla@absoluteantibody.com

Read the full story at https://www.prweb.com/releases/absolute_antibody_launches_vivopurex_recombinant_antibodies_for_in_vivo_research/prweb16811399.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Absolute Antibody Partners with the Recombinant Antibody Network to Facilitate Access to Engineered Recombinant Antibodies
2. Schulman Associates IRB Acquires Absolute Research
3. Elusive quantum transformations found near absolute zero
4. Chan Zuckerberg Biohub Choose Geneious For Best Practice NGS Antibody Pipeline
5. Singh Biotechnology Receives Second FDA Orphan Drug Designation for its Novel Single Domain Antibody for the Treatment of Osteosarcoma by Targeting Intracellular STAT3
6. Thermo Fisher Scientific Addresses the Antibody Reproducibility Crisis with Panel Discussion
7. Merck uses Genedata Biologics to Scale-Up Bispecific Antibody Discovery Programs
8. GigaGen Announces Launch of New Antibody Discovery Service at 2017 BIO International Conference
9. Newest Port Company Revolutionizing Antibody Discovery Platforms
10. SCIEX Webinar to Explore Monoclonal Antibody Glycan Analysis up to 5 Times Faster Than HILIC
11. Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research (AACR) 2017 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2020)... NEW YORK (PRWEB) , ... February 03, 2020 ... ... Quarterly Business Travel, Financial Services Firm Travel, Law Firm Travel, Technology Industry Travel ... of data findings, listed quarterly. Each Index illustrates the following statistics:, ...
(Date:1/28/2020)... ... January 28, 2020 , ... ... biopharmaceutical R&D, today announced the release of Genedata Expressionist ® 13.5 ... the implementation of Multi-Attribute Methods (MAM) for characterizing and monitoring the quality ...
(Date:1/27/2020)... ... January 27, 2020 , ... ... has secured financing from strategic investors led by Halma plc , a ... investors Sonion, TDF Ventures, GII LLC, and WSJ Joshua Fund. A representative from ...
(Date:1/24/2020)... ... January 24, 2020 , ... ... RedySmart™ mass flow meters and controllers ideal for BioPharm OEMS. ... upgrade to antiquated rotameters. These thermal instruments employ high-precision MEMS (Micro-Electro Mechanical Systems) ...
Breaking Biology Technology:
(Date:1/7/2020)... ... 07, 2020 , ... Lifecycle Biotechnologies announces the ... like what can be found in most catalogs, but rather, insightful information into ... linked to the impact it has on the global life science industry. The ...
(Date:1/2/2020)... ... January 02, 2020 , ... ... aqueous reagents, chemicals, and medias, as well as medical grade plastic products to ... tissue-based product manufacturers. , “We are excited to bring even more advantages ...
(Date:12/30/2019)... NEWPORT BEACH, Calif. (PRWEB) , ... December 30, ... ... , According to the Alzheimer’s Association:, ,     Alzheimer's disease is ... than 16 million Americans provide unpaid care for people with Alzheimer's or other ...
Breaking Biology News(10 mins):